ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	12/27/1952
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies

ARUP test code 0051033

Asialo-GM1 Antibodies, IgG/IgM	**282**	**IV H**	**(Ref Interval: 0-50)**
GM1 Antibodies, IgG/IgM	**125**	**IV H**	**(Ref Interval: 0-50)**
GM2 Antibodies, IgG/IgM	10	IV	(Ref Interval: 0-50)
GD1a Antibodies, IgG/IgM	**125**	**IV H**	**(Ref Interval: 0-50)**
GD1b Antibodies, IgG/IgM	**52**	**IV H**	**(Ref Interval: 0-50)**
GQ1b Antibodies, IgG/IgM	13	IV	(Ref Interval: 0-50)

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM

29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Asialo-GM1 Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GM1 Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GM2 Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GD1a Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GD1b Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GQ1b Antibodies, IgG/IgM	24-019-115371	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical